Genprex announces $4M registered direct offering of common stock and warrants

Genprex, Inc.

Sold 3,809,524 shares and warrants to purchase same number at $1.05 combined price.
Gross proceeds ~$4M; net proceeds for working capital.
Warrants exercisable at $1.10, expire 5 years from issuance.
Closing expected March 1, 2023; A.G.P./Alliance Global Partners as placement agent.
Offering under effective shelf registration statement (S-3).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Genprex, Inc. entered into Securities Purchase Agreement with accredited healthcare-focused institutional investor valued at aggregate gross proceeds approximately $4.0 million (effective 2023-02-26).

Action: entry
Agreement: equity purchase
Counterparty: accredited healthcare-focused institutional investor
Value: aggregate gross proceeds approximately $4.0 million
Effective: 2023-02-26

Exact text from the filing

On February 26, 2023, Genprex, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with an accredited healthcare-focused institutional investor (the “Purchaser”) pursuant to which the Company agreed to issue and sell to the Purchaser 3,809,524 shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”) and common warrants to purchase an aggregate of 3,809,524 shares of Common Stock (the “Warrants”), in a registered direct offering (the “Offering”).

View on SEC.gov

Browse all material agreements →

Genprex, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-004771

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.